

Benjamin L Maughan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2399597/publications.pdf>

Version: 2024-02-01

31
papers

622
citations

623734

14
h-index

610901

24
g-index

32
all docs

32
docs citations

32
times ranked

953
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). <i>Lancet Oncology</i> , The, 2022, 23, 899-909. | 10.7 | 26 |
| 2 | Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278. | 3.7 | 33 |
| 3 | Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2021, 22, 1625-1632. | 1.8 | 5 |
| 4 | Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 4807-4813. | 7.0 | 9 |
| 5 | Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. <i>Oncologist</i> , 2021, 26, 751-760. | 3.7 | 9 |
| 6 | Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. <i>Cancers</i> , 2021, 13, 4951. | 3.7 | 19 |
| 7 | Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 3725-3736. | 1.6 | 69 |
| 8 | Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. <i>Oncologist</i> , 2021, 26, 1006-e2129. | 3.7 | 13 |
| 9 | Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 724-726. | 1.0 | 2 |
| 10 | A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 121-e213. | 3.7 | 28 |
| 11 | Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE). <i>Journal of Clinical Oncology</i> , 2020, 38, 4240-4248. | 1.6 | 69 |
| 12 | <p>Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 3741-3749. | 1.9 | 15 |
| 13 | Pathogenic Germline DNA Repair Gene and <i>HOXB13</i> Mutations in Men With Metastatic Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 139-151. | 3.0 | 7 |
| 14 | Definitive Chemoradiotherapy for Locally Advanced, Lymph-node Positive, Nonmetastatic Penile Squamous Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e573-e584. | 1.9 | 6 |
| 15 | What men want: Qualitative analysis of what men with prostate cancer (PCa) want to learn regarding genetic referral, counseling, and testing. <i>Prostate</i> , 2020, 80, 441-450. | 2.3 | 8 |
| 16 | Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2104-2110. | 7.0 | 15 |
| 17 | Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma. <i>PLoS ONE</i> , 2019, 14, e0210415. | 2.5 | 8 |
| 18 | Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100116. | 1.7 | 29 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. <i>Current Treatment Options in Oncology</i> , 2019, 20, 14. | 3.0 | 16 |
| 20 | Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time. <i>Cancer Treatment and Research Communications</i> , 2019, 19, 100120. | 1.7 | 10 |
| 21 | Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. <i>Drugs and Aging</i> , 2019, 36, 395-401. | 2.7 | 5 |
| 22 | Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Molecular Cancer Therapeutics</i> , 2019, 18, 726-729. | 4.1 | 9 |
| 23 | The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma. <i>Translational Cancer Research</i> , 2019, 8, E1-E6. | 1.0 | 3 |
| 24 | Overview of Current and Future First-Line Systemic Therapy for Metastatic Clear Cell Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2018, 19, 6. | 3.0 | 47 |
| 25 | Incidence and Characterization of Antiandrogen Withdrawal Syndrome After Discontinuation of Treatment With Enzalutamide in Castration-resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e169-e172. | 1.9 | 7 |
| 26 | Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High-Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. <i>Oncologist</i> , 2018, 23, 1413-e151. | 3.7 | 11 |
| 27 | Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. <i>Research and Reports in Urology</i> , 2018, Volume 10, 205-217. | 1.0 | 15 |
| 28 | PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707. | 1.6 | 57 |
| 29 | Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications. <i>Oncotarget</i> , 2017, 8, 33614-33620. | 1.8 | 45 |
| 30 | Six-Month Progression-Free Survival as the Primary Endpoint to Evaluate the Activity of New Agents as Second-line Therapy for Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 130-137. | 1.9 | 27 |
| 31 | Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 308-308. | 1.6 | 0 |